sponsored
PatientsVille.com Logo

PatientsVille

Luvox Medical Research Studies

Up-to-date List of Luvox Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Luvox Medical Research Studies

Rank Status Study
1 Recruiting Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
Condition: SCHIZOPHRENIA 1 (Disorder)
Intervention: Drug: Fluvoxamine
Outcome Measures: effect of SSRI augmentation on cognitive function in schizophrenia patients;   effect of SSRI augmentation on the RNA and protein products in peripheral mononuclear cells
2 Recruiting Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine
Condition: Recurrent Depressive Disorder
Intervention: Drug: Fluvoxamine
Outcome Measures: Change of time difference between Part I and Part II of Stroop Test;   Change of total Frontal Assessment Battery score;   Proportion of patients maintained remission status;   Changes of Addenbrooke's Cognitive Examination general score;   Change of The Social Adaptation Self-evaluation Scale total score
3 Unknown  Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
Condition: Drug Interaction of Clopidogrel
Interventions: Drug: omeprazole;   Drug: Fluvoxamine;   Drug: placebo
Outcome Measure: platlet reactivity in response to clopidogrel
4 Unknown  Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)
Condition: Obsessive Compulsive Disorder
Interventions: Drug: Luvox CR;   Behavioral: Behavioral Therapy
Outcome Measure: The primary outcome measure (Y-BOCS score) will be obtained by clinician rating
5 Recruiting Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Condition: Depression
Intervention:
Outcome Measures: Prevalence of different neurological disorders associated with depression treated with Fluvoxamine (Fevarin®).;   Demographics of patients (age, gender, race, family status, education, employment).;   Change in the Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score;   Number and proportion of patients with depression symptoms change measured by Hospital Anxiety and Depression Scale (HADS);   Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score;   Global severity of illness and change in the clinical condition measured by Clinical Global Impression scale;   Number and proportion of patients with change in Clinical Global Impression scale;   Anxiety and depression symptoms score measured by Hospital Anxiety and Depression Scale (HADS);   Number and proportion of patients with anxiety symptoms change measured by Hospital Anxiety and Depression Scale (HADS)
6 Recruiting Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes
Condition: Depression
Interventions: Drug: Fluvoxamine;   Drug: Digoxin
Outcome Measure: Cmax of Fluvoxamine and of digoxin
7 Recruiting A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder
Condition: Obsessive Compulsive Disorder
Interventions: Drug: Fluvoxamine maleate;   Drug: placebo
Outcome Measures: Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score.;   Frequency of Adverse Events;   Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score stratified by each factor;   Mean change of the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score and subscore at each measurement;   Clinical Global Impression Improvement;   The proportion of subject with a ≥ 25% decrease from baseline in the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score;   The proportion of subject with a ≥ 35% decrease from baseline in the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score;   The change from baseline to each post-baseline measurement in the Children's Yale-Brown Obsessive Compulsive Scale 10-item total score;   Clinical Global Impression;   Change of Laboratory test result, Body weight, Blood pressure and Pulse rate;   Change of Laboratory test result, Body weight, Blood pressure and Pulse rate, and Electrocardiography;   A change in Frequency of Withdrawn Syndrome;   The Children's Yale-Brown Obsessive Compulsive Scale 10-item total score and sub-score
8 Recruiting Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Conditions: Obsessive-Compulsive Disorder;   Anxiety Disorders;   Mental Disorders
Interventions: Drug: Fluoxetine;   Drug: Sertraline;   Drug: Paroxetine;   Drug: Citalopram;   Drug: Fluvoxamine;   Behavioral: Exposure and Response Prevention
Outcome Measures: The change of Yale-Brown Obsessive-Compulsive Scale score;   The change of Beck Depression Inventory(BDI-II) score;   The change of Beck Anxiety Inventory(BAI) score;   The change of Stress Perceived Questionnaire (PSS-10) score;   The change of Behavioral Inhibition/Behavioral Activation System Scales score;   The change of Barratt Impulsiveness Scale 11 (BIS-11) score;   The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score;   The NEO-Five Factor Inventory-Revised (NEO-FFI-R);   The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
9 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
10 Recruiting Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: SSRI antidepressants;   Behavioral: Cognitive-Behavior Therapy
Outcome Measures: Hamilton Rating Scale for Depression (HAMD);   Magnetic Resonance Imaging
11 Recruiting Interpersonal Psychotherapy for Treatment Resistant Depression
Condition: Treatment Resistant Depression
Interventions: Other: IPT+ antidepressant drugs;   Drug: fluoxetine;   Drug: sertraline;   Drug: paroxetine;   Drug: Citalopram;   Drug: escitalopram;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Lithium;   Drug: Risperidone;   Drug: tranylcypromine;   Drug: Imipramine;   Drug: amitriptyline;   Drug: Clomipramine;   Drug: nortriptyline;   Drug: trazodone;   Drug: Mirtazapine;   Drug: sulpiride
Outcome Measures: Hamilton Depression Scale (HAM-D) - continuous;   Beck depression Inventory (BDI)
12 Recruiting Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications
Conditions: Depressive Disorder;   Lactation
Intervention: Drug: SSRI/SNRI
Outcome Measures: Evaluate the pharmacokinetics of SSRI/SNRI antidepressant drugs in breast milk secretion;   Examine neonatal adaptation;   Examine neurodevelopment;   Study of growth;   Examine early mother-infant relationship
13 Not yet recruiting The Establishment of the Objective Diagnostic Markers and Personalized Medical Intervention in Patients With Major Depressive Disorders (MDD)
Condition: Depressive Disorder, Major
Interventions: Drug: SSIRs;   Procedure: Modified Electraconvulsive therapy (MECT)
Outcome Measures: The changes of HAMD total score at 8 weeks from baseline;   The changes of HAMA total score at 8 weeks from baseline;   The change of CGI score at 8 weeks from baseline;   The change of YMRS total score at 8 weeks from baseline;   The remission rate after the intervention;   Number of participants with serious and non-serious adverse events
14 Recruiting Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.
Condition: Obsessive-Compulsive Disorder
Interventions: Drug: fluoxetine;   Behavioral: Group cognitive-behavioral therapy
Outcome Measures: Treatment response status at week 28;   Treatment response status at week 14;   Predictors of treatment response at week 28
15 Recruiting Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging
Condition: Depressive Disorder
Interventions: Behavioral: medicine combined CBT;   Drug: medicine
Outcome Measures: Hamilton Rating Scale for Depression (HAMD);   Magnetic Resonance Imaging;   The Beck Depression Inventory (BDI);   Generic Quality of Life Inventory-74
16 Not yet recruiting Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study
Condition: 1. Major Depressive Disorder.
Interventions: Device: Supplemental TMS;   Drug: Standard Medication Monotherapy
Outcome Measures: Montgomery-Åsberg Depression Rating Scale (MADRS);   Hamilton Rating Scale for Depression (HRSD)

These studies may lead to new treatments and are adding insight into Luvox etiology and treatment.

A major focus of Luvox research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Luvox